Jacob Handlos Grauslund

Author

Zealand University Hospital

Also Known As

J.H. Grauslund, Jacob Grauslund, Jacob H Grauslund, Jacob H. Grauslund, Jacob Handlos Grauslund

Publications

221

Citations

H-Index

Concepts

All Affiliations

Zealand University Hospital University of Copenhagen Copenhagen University Hospital Herlev Hospital Rigshospitalet

About

Jacob Handlos Grauslund is an author at Zealand University Hospital specializing in cancer research, radiation oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	33
2	Immunology	2	2	33
3	Pathology	2	2	33
4	Immune Surveillance	1	1	22
5	Immunodeficiencies	1	1	22

Jacob Handlos Grauslund

Publications

150

Citations

H-Index

Page 1

	Year	Citations
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms Jacob Handlos Grauslund, Morten Orebo Holmström, Nicolai Grønne Dahlager Jørgensen, Frontiers in Oncology	2021	50
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine Mathieu Gigoux, Morten Orebo Holmström, Roberta Zappasodi, Science Translational Medicine	2022	28
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial Nicolai Grønne Dahlager Jørgensen, Uffe Klausen, Jacob Handlos Grauslund, Frontiers in Immunology	2020	27
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients Lasse Hjort Jakobsen, Fredrik Ellin, Knut B. Smeland, British Journal of Haematology ImmunodeficienciesImmunologyPathologyEarly NormalizationMyc Gene Translocation	2020	22
An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial Jacob Handlos Grauslund, Morten Orebo Holmström, Evelina Martinenaite, Frontiers in Immunology	2023	12
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study Nicolai Grønne Dahlager Jørgensen, Jeanette Kaae, Jacob Handlos Grauslund, Cancers VaccinationImmune CheckpointTumor ImmunologyCancer ImmunosurveillanceMedicine	2021	11

Page 1